Cytoplasmic expression of ERβ was detected in 33% of malignant lesions, mainly in 25% of MEC samples and in 33% of ACC, followed by sporadic cases of mixed tumors and adenocarcinoma. Here, ESR2 is linked to adenocarcinoma.